<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924505</url>
  </required_header>
  <id_info>
    <org_study_id>INOD</org_study_id>
    <secondary_id>1R01DA046867-01</secondary_id>
    <nct_id>NCT03924505</nct_id>
  </id_info>
  <brief_title>Preventing Opioid Overdose Mortality in the United States</brief_title>
  <official_title>Preventing Opioid Overdose Mortality in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>RTI International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to generate knowledge regarding the process of implementing naloxone within
      syringe service programs (SSPs), and to test whether external facilitation can improve
      implementation of naloxone within SSPs throughout the country. Together, these efforts can
      improve access to naloxone for people at high risk of overdose, thereby improving our
      nation's response to the opioid overdose epidemic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to understand and improve naloxone implementation within Syringe
      Service Programs (SSPs) to reduce opioid overdose mortality in the United States. To achieve
      this goal, we will implement an external facilitation intervention that has been shown to
      improve implementation in HIV service settings. The intervention will leverage a naloxone
      implementation expert who will work with SSP organizational directors to identify barriers to
      and facilitators of achieving naloxone implementation quality and maximizing reach. We
      propose to assess the effectiveness of external facilitation, compared to dissemination of an
      implementation manual, in a national sample of SSPs in a randomized controlled trial (RCT).
      Our proposed specific aims are as follows:

      Aim 1: To characterize United States syringe service programs along the exploration,
      preparation, implementation and sustainment (EPIS) continuum for delivering naloxone.

      Aim 2: To test the effectiveness of external facilitation + dissemination of the naloxone
      implementation manual, compared with dissemination of the naloxone implementation manual
      alone, to improve the advancement of naloxone along the EPIS continuum among United States
      syringe service programs.

      Hypothesis. The dissemination and external facilitation arm will be more effective in
      advancing naloxone implementation along the EPIS continuum between baseline and 12-month
      follow-up, than the dissemination-only arm.

      To achieve these aims, 425 SSPs that are registered with the North American Syringe Exchange
      Network (NASEN) and /or receive information from harm reduction related web-based forums
      (e.g., online discussion groups, newsletters and listservs)will be asked to participate in an
      on-line cross-sectional survey and will be sent a hyperlink to the initial screening survey.
      We will use the on-line survey results to characterize the SSPs along the exploration,
      preparation, implementation and sustainment (EPIS) continuum for delivering the naloxone
      intervention (AIM 1).

      The on-line survey includes a set of questions designed to collect information to evaluate
      where the SSP falls along the EPIS continuum for naloxone delivery. SSPs in the
      Implementation (I) phase of the EPIS continuum (estimated n = 100) will be contacted by
      research staff and offered the opportunity to participate in the RCT. SSPs that are
      interested in participating in the RCT will be enrolled in the study. For those SSPs who
      agree to participate, study staff will confirm eligibility by reviewing and documenting
      responses to the screening survey.

      Following informed consent procedures, the study staff will administer the baseline survey to
      the SSP representative. The baseline survey will include questions about programmatic
      capacity, organizational culture, potential for internal champion or leader, perceived need
      for naloxone distribution within their community, and community acceptance of peer naloxone
      distribution programming. The study staff will then randomize SSPs into one of the one of the
      two study arms: (1) dissemination of the implementation manual and external facilitation for
      12 months (experimental arm; n=50) and (2) dissemination of the implementation manual only
      (control arm; n=50).

      All SSPs enrolled in the RCT will be sent a copy of the naloxone implementation manual either
      via email, hyperlink or the U.S. postal service depending on the preference of the
      participant. Those SSPs in the experimental arm will be enrolled in the EF intervention
      during which they will work directly with an OC to advance naloxone delivery as far along the
      EPIS continuum as possible during a 12-month period. The intervention will be delivered via
      phone calls, web-enabled audio and screen-sharing technology, and site visits. The key
      activities of the EF intervention include, initial SSP engagement, knowledge enhancement,
      capacity assessment, information gathering, identification of barriers and facilitators,
      development of action plans and provision of feedback, identification of funding and linkage
      to resources, and training of SSP staff.

      At the end of the 12-month intervention period, SSPs in both study arms will participate in a
      follow-up survey, conducted by study staff, to evaluate advancement of naloxone
      implementation along the EPIS continuum.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adoption of Best Practices</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of Best Practices adopted by the SSP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adoption of Best Practices</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Best Practices adopted by the SSP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Naloxone Coverage</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of SSP participants receiving a dose of naloxone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Naloxone Coverage</measure>
    <time_frame>12 months</time_frame>
    <description>Number of SSP participants receiving a dose of naloxone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Naloxone Doses Distributed to SSP participants</measure>
    <time_frame>Baseline</time_frame>
    <description>Naloxone Dispensed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Naloxone Doses Distributed to SSP participants</measure>
    <time_frame>12 months</time_frame>
    <description>Naloxone Dispensed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Opioid Overdose</condition>
  <arm_group>
    <arm_group_label>Implementation Manual and External Facilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Implementation Manual - only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Implementation Manual with External Facilitation Intervention</intervention_name>
    <description>Participating organizations will receive the implementation manual and the external facilitation (EF) intervention. The manual provides instructions for organizations wanting to implement a high quality naloxone program. The EF will assist syringe service programs to integrate naloxone delivery within their organization. As part of these efforts, we will use a measurement framework to understand naloxone delivery within SSPs along the four phases of the implementation processâ€”exploration, preparation, implementation and sustainment (EPIS).</description>
    <arm_group_label>Implementation Manual and External Facilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Implementation Manual only</intervention_name>
    <description>Participating organizations will receive the implementation manual.The manual provides instructions for organizations wanting to implement a high quality naloxone program.</description>
    <arm_group_label>Implementation Manual - only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SSPs that participate in the on-line screening survey and fall into the implementation
             phase of the EPIS continuum will be recruited into the study.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barrot Lambdin, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barrot Lambdin, PhD, MPH</last_name>
    <phone>415-848-1334</phone>
    <email>blambdin@rti.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynn Wenger</last_name>
    <phone>415-848-1319</phone>
    <email>lynndee@rti.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barrot Lambdin, PhD, MPH</last_name>
      <phone>415-848-1334</phone>
      <email>blambdin@rti.org</email>
    </contact>
    <contact_backup>
      <last_name>Lynn D Wenger, MSW, MPH</last_name>
      <phone>415-848-1319</phone>
      <email>lynndee@rti.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid Overdose Prevention</keyword>
  <keyword>Naloxone Implementation</keyword>
  <keyword>Implementation Science</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

